Holen Sie sich die Stockscreener-App
25.52
1.27%
0.32
Handel nachbörslich:
25.16
-0.36
-1.41%
Schlusskurs vom Vortag:
$25.20
Offen:
$25.01
24-Stunden-Volumen:
1.17M
Relative Volume:
0.62
Marktkapitalisierung:
$4.80B
Einnahmen:
$219.12M
Nettoeinkommen (Verlust:
$-453.82M
KGV:
-6.5436
EPS:
-3.9
Netto-Cashflow:
$-419.68M
1W Leistung:
+4.16%
1M Leistung:
+1.15%
6M Leistung:
-8.30%
1J Leistung:
-11.48%
1-Tages-Spanne:
$24.46
$25.55
1-Wochen-Bereich:
$23.35
$25.81
52-Wochen-Spanne:
$21.62
$44.32
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BridgeBio Dives on Revealing Case Study - Baystreet.ca
BridgeBio Announces Publication of Case Study Exploring - GlobeNewswire
BridgeBio's Portfolio Theory Innovation Reshapes Drug Development Strategy | BBIO Stock News - StockTitan
Achondroplasia Market Forecasted to Surge in Coming Years, - openPR
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Position Increased by Emerald Advisers LLC - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Shares Up 8.3%Still a Buy? - MarketBeat
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance Australia
(BBIO) Proactive Strategies - Stock Traders Daily
Seven PDUFA dates on FDA’s November calendar - BioCentury
BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors - Yahoo Finance
Citigroup Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - MSN
BridgeBio Pharma (NASDAQ:BBIO) Earns Buy Rating from HC Wainwright - MarketBeat
Gene therapy shows promise in Canavan disease trial By Investing.com - Investing.com Australia
Citi reiterates Buy rating on BridgeBio shares, cites clinical results By Investing.com - Investing.com Canada
Gene therapy shows promise in Canavan disease trial - Investing.com
BridgeBio Shares Positive Data from High Dose Cohort of - GlobeNewswire
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene - The Bakersfield Californian
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 - StockTitan
Investors in BridgeBio Pharma (NASDAQ:BBIO) have unfortunately lost 49% over the last three years - Yahoo Finance
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Objective long/short (BBIO) Report - Stock Traders Daily
Scotiabank Initiates Coverage of BridgeBio Pharma (BBIO) with Sector Outperform Recommendation - MSN
BridgeBio Pharma (NASDAQ:BBIO) Price Target Cut to $46.00 by Analysts at Leerink Partners - MarketBeat
Equities Analysts Offer Predictions for BridgeBio Pharma, Inc.'s Q3 2024 Earnings (NASDAQ:BBIO) - MarketBeat
Leerink Partnrs Issues Pessimistic Outlook for BBIO Earnings - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Analysts at Scotiabank - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Trading Up 4.7%Time to Buy? - MarketBeat
Transthyretin Amyloid Cardiomyopathy Market Emerging - openPR
BridgeBio Pharma (NASDAQ:BBIO) Shares Down 4.6%Here's What Happened - MarketBeat
When the Price of (BBIO) Talks, People Listen - Stock Traders Daily
Marshall Wace LLP Invests $781,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
3 Top Stocks That Could Still Rocket Higher in 2024 - AOL
Algert Global LLC Has $1.42 Million Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Oppenheimer Initiates Coverage of BridgeBio Pharma (BBIO) with Perform Recommendation - Nasdaq
BridgeBio granted Perform rating at Oppenheimer on market challenges (NASDAQ:BBIO) - Seeking Alpha
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Oppenheimer - MarketBeat
BridgeBio to Present Outcomes Data Through 42 Months from - GlobeNewswire
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions - StockTitan
Ghisallo Capital Management LLC Sells 33,750 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Position Cut by Ghisallo Capital Management LLC - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Quarry LP - Defense World
5 FDA decisions to watch in the fourth quarter - Yahoo Finance
Capital Impact Advisors LLC Reduces Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
BridgeBio completes enrollment for potential LGMD2I therapy By Investing.com - Investing.com South Africa
BridgeBio shares maintain Market Perform rating from BMO By Investing.com - Investing.com Canada
Piper Sandler keeps Overweight rating on BridgeBio Pharma stock By Investing.com - Investing.com Canada
BridgeBio shares hold ratings with positive study data By Investing.com - Investing.com Canada
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease - AOL
Early-Stage Biotech BridgeBio's Acoramidis Drives Valuation for Long-Term Investors - Morningstar
Transthyretin Amyloid Cardiomyopathy Market Size, Share, - openPR
BridgeBio Pharma's (BBIO) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):